Decreased nonspecific adhesivity, receptor-targeted therapeutic nanoparticles for primary and metastatic breast cancer
Open Access
- 17 January 2020
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (3) , eaax3931
Abstract
DART nanoparticles overcome critical drug delivery barriers for primary tumors and brain metastases.Keywords
Funding Information
- National Institutes of Health (R37 CA218617)
- National Institutes of Health (R01NS107813)
This publication has 59 references indexed in Scilit:
- Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapyNature Communications, 2017
- Protein corona: a new approach for nanomedicine designInternational Journal of Nanomedicine, 2017
- Non-specific binding and steric hindrance thresholds for penetration of particulate drug carriers within tumor tissueJournal of Controlled Release, 2016
- Breast cancer brain metastases: biology and new clinical perspectivesBreast Cancer Research, 2016
- Surface plasmon resonance as a high throughput method to evaluate specific and non-specific binding of nanotherapeuticsJournal of Controlled Release, 2015
- Paclitaxel-loaded PCL–TPGS nanoparticles: In vitro and in vivo performance compared with Abraxane®Colloids and Surfaces B: Biointerfaces, 2014
- Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast CancerPLOS ONE, 2013
- Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAbJournal of Cancer Research and Clinical Oncology, 2012
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJournal of Clinical Investigation, 2011
- Prevention of Antibody-Mediated Elimination of Ligand-Targeted Liposomes by Using Poly(Ethylene glycol)-Modified LipidsThe Journal of Pharmacology and Experimental Therapeutics, 2002